Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements review discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://davidy604rep1.blog-mall.com/profile